Abstract
Comparison of post–intensive care syndrome between critically ill survivors with or without coronavirus disease 2019 (CovP and CovN, respectively) showed that fewer CovP were able to return to work full time at >1 year and none at <1 year after discharge and that the majority of CovP survivors were able to work part time during both evaluation periods compared to CovN.
Keywords: COVID-19, post–intensive care syndrome, sepsis
Advances in the management of sepsis have led to a substantial population of survivors. Prognosis of these survivors following discharge varies, with half of the patients recovering, a third dying within the first year, and one-sixth remaining with severe persisting impairments [1]. These patients with post–intensive care syndrome (PICS) have a higher incidence of new cognitive and functional impairments and mental health issues, including anxiety, depression, and posttraumatic stress disorder (PTSD), along with a higher risk of rehospitalization within 90 days [1]. More than 1200 patients with coronavirus disease 2019 (COVID-19) infection were hospitalized in our New York City public hospital in the Bronx between 1 March and 1 May 2020, with 23% of patients being critically ill and managed in conventional intensive care units (ICUs) or Flex ICUs due to severe sepsis or acute respiratory distress syndrome. The majority of these patients received mechanical ventilation. It has been described among different cohorts from New York City that the fatality rate in patients with COVID-19 and mechanical ventilation during the early surge of the pandemic was as high as 80%; our hospital did not differ from this rate [2]. The survivors of COVID-19 infection are likely to suffer long-lasting morbidity, which may be comparable to other non–COVID-19–related sepsis survivors. Data on the long-term impact of COVID-19 infection are evolving as the pandemic is now transitioning to the endemic state.
Our prospective study aims to compare PICS between survivors of mechanically ventilated COVID-19 infection and similar non–COVID-19–related sepsis survivors.
METHODS
This is a single center study including all mechanically ventilated adult patients with and without COVID-19 infection who were discharged alive from January to September 2020. Following institutional review board approval, a validated survey to assess functional limitations, new medical conditions, mental health status, quality of life, and rehospitalizations was administered via telephone to consenting patients after discharge. The validated survey included the Patient Health Questionnaire 9 (PHQ-9), General Anxiety Disorder 7 (GAD-7), PTSD score, and Karnofsky Performance Status scale as well as other questions that focused on describing functional ability, change in consistency of diet, rehospitalization, worsening of comorbidities, new-onset cardiovascular problems, ability to return to work (part time and full time), and new need of assistance for activities of daily living (ADLs) or instrumental activities of daily living (IADLs). The study population was divided for analysis into <1 year postdischarge and >1 year postdischarge. For analysis, patients reporting a Karnofsky score of <70 were considered unable to carry out normal activities without signs and symptoms of disease and requiring a varying amount of assistance with inability to do active work. Descriptive statistics including χ2 test for categorical variables and t test for continuous variables were used, and multiple logistic regression was performed to determine odds ratio (OR).
RESULTS
Three hundred nine mechanically ventilated patients were discharged alive in the study period (132 with COVID-19 infection [CovP] and 177 without COVID-19 infection [CovN]). Nineteen (11%) patients in the CovN cohort and 9 patients (7%) in the CovP cohort died within 1 year of discharge. With a 46% response rate, our study cohort included 70 patients in the CovN group and 52 patients in the CovP group.
Table 1 describes the baseline characteristics of patients interviewed <1 year from discharge (15 CovP and 43 CovN). The CovP cohort had higher rate of obesity and median Charlson Comorbidity Index compared to CovN. Patients who were CovP had new functional decline (OR, 2.5; P = .13), required help with ADLs/IADLs (OR, 3.12; P = .06), and had an increased likelihood for Karnofsky score <70 (OR, 3.1; P = .06) (Table 2). They also had a higher incidence of new cognitive impairment, speech difficulty, and a decrease in executive function compared to CovN. A decreased risk of rehospitalizations (OR, 0.12; P = .025) and aspiration pneumonia (OR, 0.37; P = .35) was seen in the CovP compared to CovN patients. The CovP cohort had less depression (OR, 0.79; P = .05), less anxiety (OR, 0.70; P = .05), and higher PTSD (OR, 6.46; P = .09) compared to CovN. None of the CovP patients were able to return to work full time at <1 year, with majority able to return part time/per diem. Thirty-seven percent of CovN patients were unable to return to work (P < .001).
Table 1.
Baseline Characteristics of Coronavirus Disease 2019 (COVID-19)–Positive and COVID-19–Negative Patients Who Survived Intensive Care Unit Stay and Were Interviewed at <1 or >1 Year
| Characteristic | <1 y | >1 y | ||||||
|---|---|---|---|---|---|---|---|---|
| Overall (n = 59) |
COVID-19 Positive (n = 44) |
COVID-19 Negative (n = 15) |
P Value | Overall (n = 63) |
COVID-19 Positive (n = 26) |
COVID-19 Negative (n = 37) | P Value | |
| Time to survey, y, median (IQR) | 0.75 (0.63–0.86) | 0.72 (0.63–0.86) | 0.80 (0.64–0.87) | .183 | 1.44 (1.37–1.48) | 1.49 (1.21–1.60) | 1.44 (1.40–1.47) | .645 |
| Age, y, median (IQR) | 57.0 (50.0–63.0) | 56.5 (47.3–63.0) | 57.0 (54.0–62.0) | .979 | 58.0 (47.0–65.0) | 59.5 (50.5–68.0) | 56.0 (42.5–64.0) | .222 |
| Male sex | 29 (49.2) | 20 (45.5) | 9 (60.0) | .330 | 19 (30.2) | 10 (30.8) | 9 (24.9) | .229 |
| BMI, kg/m2, median (IQR) | 30.0 (25.2–36.0) | 29.1 (24.3–33.8) | 34.4 (29.7–48.8) | .003 | 31.7 (27.2–35.9) | 30.2 (22.4–35.1) | 32.3 (28.9–35.9) | .189 |
| CCI score, median (IQR) | 4.0 (2.0–7.0) | 4.0 (1.3–7.0) | 7.0 (2.0–15.0) | .073 | 3.0 (1.0–5.0) | 3.0 (2.0–5.3) | 2.0 (0.0–5.0) | .116 |
| Hypertension | 27 (45.8) | 24 (54.5) | 3 (20.0) | .020 | 43 (68.3) | 17 (65.4) | 26 (70.3) | .682 |
| Diabetes mellitus | 20 (33.9) | 16 (36.4) | 4 (26.7) | .493 | 31 (49.2) | 12 (46.2) | 19 (51.4) | .685 |
| COPD | 26 (44.1) | 19 (43.2) | 7 (46.7) | .814 | 12 (19.0) | 7 (26.9) | 5 (13.5) | .182 |
| Chronic kidney disease | 13 (22.0) | 7 (15.9) | 6 (40.0) | .052 | 8 (12.7) | 5 (19.2) | 3 (8.1) | .192 |
| Liver disease | 2 (3.4) | 2 (4.5) | 0 (0.0) | .401 | 2 (3.2) | 1 (3.8) | 1 (2.7) | .659 |
| HIV | 2 (3.4) | 2 (4.5) | 0 (0.0) | .401 | 3 (4.8) | 2 (7.7) | 1 (2.7) | .368 |
| Seizure disorder | 2 (3.4) | 2 (4.5) | 0 (0.0) | .401 | 2 (3.2) | 2 (7.7) | 0 (0) | .166 |
| CHF | 8 (13.6) | 7 (15.9) | 1 (6.7) | .367 | 12 (19) | 10 (38.5) | 2 (5.4) | .001 |
| Prior mental illness | 11 (18.6) | 10 (22.7) | 1 (6.7) | .168 | 6 (9.5) | 4 (15.4) | 2 (5.4) | .186 |
| Length of stay, d, median (IQR) | 15.0 (6.0–28.0) | 13.0 (5.0−25.8) | 15.0 (14.2–58.0) | .117 | 15.0 (4.0–26.0) | 3.0 (2.0–8.0) | 23.0 (16.0–30.8) | .001 |
| Length of mechanical ventilation, d, median (IQR) | 4.0 (3.0–9.0) | 4.0 (3.0–8.0) | 5.0 (3.0–14.0) | .174 | 9.0 (3.0–17.0) | 3.0 (2.0–6.3) | 14.0 (9.0–29.0) | .001 |
| Apache score on ICU admission, median (IQR) | 14.0 (10.0–21.0) | 14.5 (10.5–20.8) | 12.0 (3.0–24.0) | .166 | 12.0 (6.0–18.0) | 8.0 (6.0–12.0) | 15.0 (6.0–20.0) | .124 |
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range.
Table 2.
Comparison of Outcomes Between Coronavirus Disease 2019 (COVID-19)–Positive and COVID-19–Negative Survivors of Intensive Care Unit Stay, Stratified by Time After Discharge
| Outcome | <1 y | >1 y | ||||||
|---|---|---|---|---|---|---|---|---|
| COVID-19 Positive (n = 15) |
COVID-19 Negative (n = 43) |
OR (95% CI) |
P Value | COVID-19 Positive (n = 37) |
COVID-19 Negative (n = 27) |
OR (95% CI) |
P Value | |
| New functional decline | 9 (60) | 16 (37) | 2.5 (.76–8.44) | .131 | 22 (60) | 19 (70) | .62 (.22–1.77) | .371 |
| Karnofsky/quality of life | 9 (60) | 14 (33) | 3.1 (.92–10.46) | .067 | 23 (62) | 20 (74) | 0.58 (.19–1.71) | .319 |
| New cognitive deficiency | 5 (33) | 10 (23) | 1.7 (.46–5.97) | .445 | 15 (41) | 10 (37) | 1.16 (.42–3.22) | .777 |
| New speech difficulty | 4 (27) | 8 (19) | 1.59 (.40–6.31) | .509 | 6 (16) | 4 (15) | 1.11 (.28–4.40) | .879 |
| New decline in executive function | 3 (20) | 6 (14) | 1.54 (.33–7.13) | .580 | 8 (22) | 8 (30) | 0.66 (.21–2.04) | .466 |
| New attention deficit | 3 (20) | 9 (21) | 0.94 (.22–4.08) | .939 | 5 (14) | 6 (22) | 0.55 (.15–2.02) | .366 |
| Requires new help with IADLs/ADLs | 9 (60) | 14 (33) | 3.12 (.92–10.46) | .067 | 13 (35) | 11 (41) | 0.78 (.28–2.19) | .648 |
| Readmission | 1 (7) | 16 (37) | 0.12 (.01–1.01) | .051 | 6 (16) | 6 (22) | 0.68 (.19–2.39) | .545 |
| Worsening comorbidities | 2 (13) | 9 (21) | 0.58 (.11–3.06) | .522 | 8 (22) | 12 (44) | 0.35 (.12–1.03) | .056 |
| New cardiovascular events | 3 (20) | 3 (7) | 3.33 (.59–18.71) | .171 | 5 (14) | 4 (15) | 0.89 (.22–3.72) | .882 |
| New depression | 0 | 9 (21) | 0.79 | .999 | 0 | 0 | … | |
| New anxiety | 1 | 10 (21) | 0.79 | .999 | 0 | 0 | … | |
| New PTSD | 2 (13) | 1 (2) | 6.46 (.54–77.14) | .140 | 3 (8) | 7 (26) | 0.25 (.06–1.09) | .065 |
| New soft/liquid diet | 3 (20) | 3 (7) | 3.33 (.59–18.71) | .171 | 0 | 2 (7) | 0.93 | .999 |
| New aspiration pneumonia | 1 (7) | 7 (16) | 0.37 (.04–3.26) | .369 | 2 (5) | 3 (11) | 0.46 (.07–2.95) | .410 |
| Return to work | … | … | <.001 | … | … | … | .003 | |
| Full time | 0 | 15 (35) | … | 4 (11) | 9 (33) | … | ||
| Part time | 10 (67) | 6 (14) | … | 5 (14) | 7 (26) | … | ||
| Per diem | 3 (20) | 6 (14) | … | 15 (40) | 0 | … | ||
| None | 2 (13) | 16 (37) | … | 13 (35) | 11 (41) | … | ||
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ADLs, activities of daily living; CI, confidence interval; COVID-19, coronavirus disease 2019; IADLs, instrumental activities of daily living; OR, odds ratio; PTSD, posttraumatic stress disorder.
Thirty-seven CovP and 27 CovN patients were contacted after 1 year of discharge (Table 1). Both the CovP and CovN patients in this group were comparable except for increased length of mechanical ventilation and stay in the CovP subgroup. CovP patients had reduced likelihood of functional decline (OR, 0.68; P = .37), Karnofsky score <70 (OR, 0.58; P = .32), and assistance with ADLs/IADLs (OR, 0.78; P = .65) compared to CovN. New cognitive improvement (OR, 1.16; P = .8) and new speech difficulty (OR, 1.11; P = .87) remained higher in CovP after 1 year. CovP patients had reduced likelihood for rehospitalizations (OR, 0.68; P = .54), aspiration pneumonia (OR, 0.457; P = .4), and worsening comorbidities (OR, 0.35; P = .05) compared to CovN (Table 2). None of the participants in either subcohort had new-onset depression or anxiety, whereas PTSD was lower in the CovP subgroup (OR, 0.25; P = .05) at >1 year. Only 11% of CovP patients were able to return to work full time after 1 year in comparison with 33% of CovN, and 35% of CovP patients were unable to return to work at all (P = .003).
Using return to work full time as reference, multiple logistic regression analysis demonstrated COVID-19 infection as an independent predictor factor of ability to return to work part time when adjusted to multiple confounders (Supplementary Table 1 and 2).
DISCUSSION
Our comparative study of mechanically ventilated sepsis survivors interviewed before and after 1 year of discharge demonstrated higher odds, though not statistically significant, of new functional decline, assistance with ADLs/IADLs, cognitive impairment, reduced executive function, and speech difficulty in the CovP cohort at <1 year; these impairments were not observed in the cohort interviewed after 1 year. Rehospitalizations consistently remained higher in the CovN cohort during both time periods. Remarkably, new-onset depression and anxiety were absent in both cohorts after 1 year of discharge, though CovN patients were more likely to have depression/anxiety at <1 year. However, our most remarkable observation was the significant difference between the 2 cohorts in the ability to return to work; although overall fewer CovP patients were able to return to work full time at >1 year and none at <1 year, this cohort was predominantly able to return to work part time during both evaluation periods compared to CovN. The inability to work at all was higher among CovN patients in both time periods.
Survivorship after ICU and hospital discharge is a major burden to families and healthcare due to short- and long-term physical, cognitive, and mental health impact leading to high rates health care utilization. The inability to return to work in the same capacity, along with the decline in cognition and executive function, is a risk to steady income for our minority low-income community in the South Bronx. While COVID-19 singularly impacted the return to work, the disability appears to be dynamic and unpredictable with the possibility of more people with disabilities over time as the pandemic continues. Though there is much to learn, our findings are similar to a previous Dutch study demonstrating persistent physical, mental, and cognitive impairments among patients with 1-year survival following ICU treatment for COVID-19 [2]. While the Americans with Disabilities Act requires employers to reasonably accommodate people with disabilities, an unprecedented problem like long COVID will need systemic solutions including more funding to expand Medicaid and other programs. There is also an overarching need to prepare and educate our population to the long-term impact of COVID-19 infection and acknowledge their inability to return to pre–COVID-19 jobs/careers. Innovative rehabilitative pathways for patients discharged from the ICU will ensure early recognition of the sequelae and direct appropriate treatment to improve their physical and mental functional status [3].
Limitations of our study include single-center design and small sample size, which can impact the generalizability. Though we used validated surveys, there is a potential for reporting bias simply by nature of the design.
CONCLUSIONS
Our hospital, a regional safety-net hospital in the South Bronx, had been at the epicenter of the pandemic and serves a low-socioeconomic, minority-predominant population. While the data recovered are part of the ongoing discovery of the short- and long-term impact of COVID-19 infection, our findings help to define PICS secondary to COVID-19 infection as a separate category from non–COVID-19 infections. There is an evident need to provide individualized care, counseling, and education to patients who find themselves with new cardiovascular conditions, cognitive decline, and new functional baselines as they continue to recover. Early rehabilitation and timely allocation of adequate resources and support to the affected population, including revision of federal/state benefits programs, would be a step in the right direction.
Supplementary Material
Contributor Information
Sebastian Ocrospoma Heraud, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Virali Shah, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Victor Perez-Gutierez, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Mohannad Al-Khateeb, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Sebastian Gandarillas Fraga, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Afsheen Afzal, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Mayer Rubin, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Sherida Edding, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Jessica Nino, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Ali Horoub, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Nushra Paracha, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Manmeet Gujral, Department of Critical Care, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Nail Cemalovic, Department of Critical Care, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Vidya Menon, Department of Medicine, New York City Health + Hospitals/Lincoln Medical Center, Bronx, New York, USA.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
Author contributions. V. M., V. P.-G., M. G., and N. C. designed the study. S. O. H., V. P.-G., M. R., N. P., M. A., S. G. F., J. N., S. E., and A. H. interviewed the participants. Data were analyzed by V. P.-G., V. S., and A. A. and interpreted by V. M., V. P.-G., S. O. H., V. S., and A. A. The manuscript was written by V. S., S. O. H., and V. M. and reviewed by all co-authors.
Acknowledgments. We would like to thank the nursing staff, patient care associates, and the physicians who were involved in the care of these patients during their intensive care unit stay at our hospital.
Financial support. No financial support was received for the study.
Ethics approval. The research was carried out and granted ethical approval by the Lincoln Hospitals Institutional Review Board (IRB number 20-041). The study was conducted in accordance with the Declaration of Helsinki.
Patient consent. Verbal consent to participate was obtained from participants prior to administering the telephonic questionnaires.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
References
- 1. Prescott HC, Angus DC. Enhancing recovery from sepsis. JAMA 2018; 319:62. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Heesakkers H, Van Der Hoeven JG, Corsten S, et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA 2022; 327:559. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Needham DM, Feldman DR, Kho ME. The functional costs of ICU survivorship. Am J Respir Crit Care Med 2011; 183:962–4. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
